| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Atherosclerosis | |||||
| Hypercholesterolemia | |||||
| Hyperlipoproteinemia Type II | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Hyperlipoproteinemias | |||||
| 3 | More general conditions related to this trial | ||||
| Arterial Occlusive Diseases | |||||
| Arteriosclerosis | |||||
| Cardiovascular Diseases | |||||
| Dyslipidemias | |||||
| Genetic Diseases, Inborn | |||||
| Hyperlipidemias | |||||
| Lipid Metabolism Disorders | |||||
| Lipid Metabolism, Inborn Errors | |||||
| Metabolic Diseases | |||||
| Metabolism, Inborn Errors | |||||
| Vascular Diseases | |||||
| 4 | Interventions listed in this trial | ||||
| ezetimibe (plus simvastatin) | |||||
| placebo (plus simvastatin) | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| Ezetimibe | |||||
| Simvastatin | |||||
| 6 | More general drug interventions related to this trial | ||||
| Anticholesteremic Agents | |||||
| Antilipemic Agents | |||||
| Antimetabolites | |||||
| Enzyme Inhibitors | |||||
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Pharmacologic Actions | |||||
| Therapeutic Uses | |||||
| 7 | Sponsors listed in this trial | ||||
| Schering-Plough | |||||
| Merck | |||||
|
